Avalglucosidase alfa vs alglucosidase alfaFVC (% predicted) Change from baseline · adults with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 100 participantsModerate
Alglucosidase alfa vs placeboFVC (% predicted) Change from baseline · 90 people with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 90 participantsModerate
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placeboFVC (% predicted) Change from baseline · 13 people with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 5 participantsVery low
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placeboFVC (% predicted) Change from baseline · 13 people with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 11 participantsVery low